Effect of Low-Density Lipoprotein Apheresis on Plasma Levels of Apolipoprotein E4

American Journal of Cardiology

Volumn 105, Issue 11, 2010, Pages 1585-1587

  Moriarty, Patrick M ^a   Luyendyk, James P ^a   Gibson, Cheryl A ^a   Backes, James M ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ADULT; APHERESIS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LOW DENSITY LIPOPROTEIN APHERESIS; MALE; PRIORITY JOURNAL;

APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 77952325552     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.01.018     Document Type: Article

References (36)

1. Davignon J. Apolipoprotein E and atherosclerosis: beyond lipid effect. Arterioscler Thromb Vasc Biol 25 (2005) 267-269
2. Mahley R.W., and Rall Jr. S.C. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1 (2000) 507-537
3. Lindahl G., Mailly F., Humphries S., and Seed M. Apolipoprotein E phenotype and lipoprotein(a) in familial hypercholesterolaemia: implication for lipoprotein(a) metabolism. J Clin Invest 72 (1994) 631-638
4. Morrow J.A., Hatters D.M., Lu B., Hochtl P., Oberg K.A., Rupp B., and Weisgraber K.H. Apolipoprotein E4 forms a molten globule: a potential basis for its association with disease. J Biol Chem 277 (2002) 50380-50385
5. Wilson P.W., Schaefer E.J., Larson M.G., and Ordovas J.M. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vasc Biol 16 (1996) 1250-1255
6. deCarli C., Reed T., Miller B.L., Wolf P.A., Swan G.E., and Carmelli D. Impact of apolipoprotein E epsilon4 and vascular disease on brain morphology in men from the NHLBI twin study. Stroke 30 (1999) 1548-1553
7. Seftel H.C., Baker S.G., Jenkins T., and Mendelsohn D. Prevalence of familial hypercholesterolemia in Johannesburg Jews. Am J Med Genet 34 (1989) 545-547
8. Streja D., Steiner G., and Kwiterovich Jr. P.O. Plasma high-density lipoproteins and ischemic heart disease: studies in a large kindred with familial hypercholesterolemia. Ann Intern Med 89 (1978) 871-880
9. Eto M., Watanabe K., Chonan N., and Ishii K. Familial hypercholesterolemia and apolipoprotein E4. Atherosclerosis 72 (1988) 123-128
10. Thompson G.R. LDL apheresis. Atherosclerosis 167 (2003) 1-13
11. Davidson W.S., Sparks D.L., Lund-Katz S., Phillips M.C., Davidson W.S., Sparks D.L., Lund-Katz S., and Phillips M.C. The molecular basis for the difference in charge between pre-beta- and alpha-migrating high density lipoproteins. J Biol Chem 269 (1994) 8959-8965
12. Settasatian N., Barter P.J., and Rye K.A. Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein. J Lipid Res 49 (2008) 115-126
13. Matsuura F., Wang N., Chen W., Jiang X.C., and Tall A.R. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest 116 (2006) 1435-1442
14. Hirano K., Yamashita S., and Matsuzawa Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol 11 (2000) 589-596
15. 1 by zonal ultracentrifugation. J Lipid Res 23 (1982) 903-910
16. Mahley R.W., Innerarity T.L., Weisgraber K.H., and Fry D.L. Canine hyperlipoproteinemia and atherosclerosis: accumulation of lipid by aortic medial cells in vivo and in vitro. Am J Pathol 87 (1977) 205-226
17. Guyton J.R., Miller S.E., Martin M.E., Khan W.A., Roses A.D., and Strittmatter W.J. Novel large apolipoprotein E-containing lipoproteins of density 1.006-1.060 g/ml in human cerebrospinal fluid. J Neurochem 70 (1998) 1235-1240
18. Koch S., Donarski N., Goetze K., Kreckel M., Stuerenburg H.J., Buhmann C., and Beisiegel U. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res 42 (2001) 1143-1151
19. Gong J.S., Morita S.Y., Kobayashi M., Handa T., Fujita S.C., Yanagisawa K., and Michikawa M. Novel action of apolipoprotein E (ApoE): ApoE isoform specifically inhibits lipid-particle-mediated cholesterol release from neurons. Mol Neurodegener 2 (2007) 9
20. Mamotte C.D., Sturm M., Foo J.I., van Bockxmeer F.M., and Taylor R.R. Comparison of the LDL-receptor binding of VLDL and LDL from apoE4 and apoE3 homozygotes. Am J Physiol 276 (1999) E553-E557
21. Altenburg M., Arbones-Mainar J., Johnson L., Wilder J., Maeda N., and Human L.D.L. Receptor enhances sequestration of ApoE4 and VLDL remnants on the surface of hepatocytes but not their internalization in mice. Arterioscler Thromb Vasc Biol 28 (2008) 1104-1110
22. Geiss H.C., Bremer S., Barrett P.H., Otto C., and Parhofer K.G. In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis. J Lipid Res 45 (2004) 1459-1467
23. Koizumi J., Inazu A., Fujita H., Takeda M., Uno Y., Kajinami K., Mabuchi H., and Takeda R. Removal of apolipoprotein E-enriched high density lipoprotein by LDL-apheresis in familial hypercholesterolaemia: a possible activation of the reverse cholesterol transport system. Atherosclerosis 74 (1988) 1-8
24. Hershcovici T., Schechner V., Orlin J., Harell D., Beigel Y., Hershcovici T., Schechner V., Orlin J., Harell D., and Beigel Y. Effect of different LDL-apheresis methods on parameters involved in atherosclerosis. J Clin Apher 19 (2004) 90-97
25. Krimbou L., Tremblay M., Davignon J., and Cohn J.S. Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-beta1-LpE, pre-beta2-LpE, and alpha-LpE. J Lipid Res 38 (1997) 35-48
26. Cardin A.D., Hirose N., Blankenship D.T., Jackson R.L., Harmony J.A., Sparrow D.A., and Sparrow J.T. Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. Biochem Biophys Res Commun 134 (1986) 783-789
27. Howlett G.J., and Moore K.J. Untangling the role of amyloid in atherosclerosis. Curr Opin Lipidol 17 (2006) 541-547
28. Cabana V.G., Feng N., Reardon C.A., Lukens J., Webb N.R., de Beer F.C., and Getz G.S. Influence of apoA-I and apoE on the formation of serum amyloid A-containing lipoproteins in vivo and in vitro. J Lipid Res 45 (2004) 317-325
29. Navab M., Berliner J.A., Subbanagounder G., Hama S., Lusis A.J., Castellani L.W., Reddy S., Shih D., Shi W., Watson A.D., van Lenten B.J., Vora D., and Fogelman A.M. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21 (2001) 481-488
30. Abe-Dohmae S., Kato K.H., Kumon Y., Hu W., Ishigami H., Iwamoto N., Okazaki M., Wu C.A., Tsujita M., Ueda K., and Yokoyama S. Serum amyloid A generates high density lipoprotein with cellular lipid in an ABCA1- or ABCA7-dependent manner. J Lipid Res 47 (2006) 1542-1550
31. Morrow D.A., Rifai N., Antman E.M., Weiner D.L., McCabe C.H., Cannon C.P., and Braunwald E. Serum amyloid A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 35 (2000) 358-362
32. Ancsin J.B., and Kisilevsky R. The heparin/heparan sulfate-binding site on apo-serum amyloid A: implications for the therapeutic intervention of amyloidosis. J Biol Chem 274 (1999) 7172-7181
33. Palumbo B., Cardinali L., and Sinzinger H. LDL-apheresis removes serum amyloid P and A in hypercholesterolemic patients. Thromb Res 97 (2000) 491-494
34. Navab M., Ananthramaiah G.M., Reddy S.T., van Lenten B.J., Ansell B.J., Hama S., Hough G., Bachini E., Grijalva V.R., Wagner A.C., Shaposhnik Z., and Fogelman A.M. The double jeopardy of HDL. Ann Med 37 (2005) 173-178
35. Navab M., Reddy S.T., van Lenten B.J., Anantharamaiah G.M., and Fogelman A.M. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 50 (2009) S145-S149
36. Opole I.O., Belmont J.M., Kumar A., and Moriarty P.M. Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol. Am J Cardiol 100 (2007) 1416-1418